Zafgen’s obesity drug succeeds in mid-stage trial
(Reuters) – Drug developer Zafgen Inc said on Thursday that its drug to treat obesity in diabetic patients met the main goal of reducing body weight. Patients given 1.8 mg and 1.2 mg doses of the drug, beloranib, experienced 12.7 and 13.5 percent reduction in body weight, respectively. Last month, Zafgen said the drug was also successful in treating Prader-Willi syndrome (PWS), the most common genetic cause of life-threatening obesity, in a late-stage trial.